Cocrystal Pharma, Inc. Common Stock (COCP) Stock Price

COCPStock

$1.13−29.14%52W

Market Cap$21.77M

P/E—

PEG Ratio—

Div yield—

Beta1.50

COCP Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)2.02%

Price vs S&P 500 (4W)15.68%

VGM Score40.61

Book Value / Share (Quarterly)$0.30

P/TBV (Annual)1.61x

Indicated Dividend (Annual)$0.00

Cash Flow / Share (Quarterly)$-0.55

Price vs S&P 500 (YTD)1.42%

Gross Margin (TTM)41.18%

Net Profit Margin (TTM)-1021.78%

EPS (TTM)$-0.73

10-Day Avg Trading Volume0.07M

EPS Excl Extra (TTM)$-0.73

EPS (Annual)$-1.80

ROI (Annual)-189.02%

Gross Margin (Annual)21.33%

Net Profit Margin (5Y Avg)-12981.54%

Cash / Share (Quarterly)$0.34

ROA (Last FY)-133.77%

EBITD / Share (TTM)$-0.74

ROE (5Y Avg)-78.39%

Operating Margin (TTM)-1047.11%

Cash Flow / Share (Annual)$-0.60

P/B Ratio3.69x

P/B Ratio (Quarterly)3.38x

Net Income / Employee (Annual)$-1,800,000

EV / Revenue (TTM)46.59x

Net Interest Coverage (TTM)-3883.00x

ROA (TTM)-97.86%

EV / EBITDA (TTM)1048.26x

EPS Incl Extra (Annual)$-1.80

Current Ratio (Annual)3.68x

Quick Ratio (Quarterly)2.48x

3-Month Avg Trading Volume0.10M

52-Week Price Return-29.14%

Revenue / Employee (TTM)$22,500

Tangible BV / Share (Quarterly)$26.76

P/S Ratio (Annual)7.55x

Asset Turnover (Annual)0.04x

52-Week High$2.67

Operating Margin (5Y Avg)-26916.68%

EPS Excl Extra (Annual)$-1.80

CapEx CAGR (5Y)-45.07%

26-Week Price Return13.27%

Quick Ratio (Annual)3.53x

13-Week Price Return-1.77%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)2.66x

Enterprise Value$10.48M

Asset Turnover (TTM)0.03x

Book Value / Share Growth (5Y)-44.72%

Revenue / Employee (Annual)$0

Pretax Margin (Annual)-480.10%

Cash / Share (Annual)$0.51

3-Month Return Std Dev53.82%

Net Income / Employee (TTM)$-882,900

ROE (Last FY)-189.02%

Net Interest Coverage (Annual)-89.72x

EPS Basic Excl Extra (Annual)$-1.80

P/FCF (TTM)7.62x

Receivables Turnover (TTM)0.00x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-0.73

Receivables Turnover (Annual)0.00x

ROI (TTM)-150.61%

P/S Ratio (TTM)67.41x

Pretax Margin (5Y Avg)-16894.02%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$26.76

Price vs S&P 500 (52W)-47.45%

Year-to-Date Return13.38%

5-Day Price Return2.78%

EPS Normalized (Annual)$-1.80

ROA (5Y Avg)-64.43%

Net Profit Margin (Annual)-480.10%

Month-to-Date Return35.37%

Cash Flow / Share (TTM)$-1.95

EBITD / Share (Annual)$-1.79

Operating Margin (Annual)-477.11%

LT Debt / Equity (Annual)0.01x

ROI (5Y Avg)-78.38%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-0.73

P/TBV (Quarterly)1.61x

P/B Ratio (Annual)2.13x

Inventory Turnover (TTM)4.43x

Pretax Margin (TTM)-1021.78%

Book Value / Share (Annual)$0.46

Price vs S&P 500 (13W)-4.56%

Beta1.50x

Revenue / Share (TTM)$0.02

ROE (TTM)-150.61%

52-Week Low$0.76

vGradeD

mGradeC

vgmGradeC

COCP Earnings Surprise History

Q2 25-0.20est. -0.30

Q3 25-0.19est. -0.21

Q4 25-0.17est. -0.17

Q1 26-0.17est. -0.15

Q2 26-0.23est. -0.17

COCP Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.13

4.14

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
COCPCocrystal Pharma, Inc. Common Stock	D	—	C	$1.13
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Cocrystal Pharma, Inc. Common Stock

Cocrystal Pharma develops novel antiviral therapeutics targeting influenza, hepatitis C, and norovirus using structure-based drug design and proprietary technology platforms. The company leverages Nobel Prize-winning expertise to create first-in-class and best-in-class antiviral drugs. Its lead program, CC-31244, is an oral broad-spectrum replication inhibitor in clinical development.